You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君聖泰醫藥-B(02511.HK)擬折價15%配股總籌1.326億港元 推進HTD1801臨牀開發及商業化
格隆匯 06-26 07:07

格隆匯6月26日丨君聖泰醫藥-B(02511.HK)發佈公告,2025年6月26日,公司與配售代理訂(即國信證券(香港)、國證國際及一盈證券)立配售協議,據此,按配售協議的條款並在配售協議所載條件的規限下,公司同意發行配售股份,而配售代理已分別單獨同意作爲公司的代理,按盡力基準促使不少於六名獨立承配人認購最多6000萬股配售股份,配售價爲每股配售股份2.21港元。配售股份將由公司根據一般授權配發及發行。

假設於本公告日期起直至配售完成日期止公司已發行股本並無變動,則6000萬股配售股份相當於公司現有已發行股本的約11.66%;及經配發及發行配售股份擴大後已發行股本總額的約10.44%。每股配售股份2.21港元的配售價較6月26日在聯交所所報收市價每股2.60港元折讓約15.00%。

假設所有配售股份均獲發行,預期配售所得款項總額合共約爲1.326億港元,而預期配售所得款項淨額合共約爲1.31億港元。公司擬將配售所得款項淨額用於集團管線產品熊去氧膽小檗鹼(HTD1801)的臨牀開發及商業化。HTD1801是公司自主研發的、一流的腸肝抗炎及代謝調節劑的先導化合物。董事相信,配售將有助增強集團的流動資金及財務狀況,從而使集團能繼續爲HTD1801的臨牀開發撥資並實現商業化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account